Provided by Tiger Trade Technology Pte. Ltd.

RenovoRx Inc

1.37
-0.0200-1.44%
Post-market: 1.400.0300+2.19%19:30 EDT
Volume:591.01K
Turnover:797.24K
Market Cap:61.72M
PE:-4.42
High:1.41
Open:1.35
Low:1.28
Close:1.39
52wk High:2.59
52wk Low:0.7006
Shares:45.05M
Float Shares:39.17M
Volume Ratio:1.28
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3096
EPS(LYR):-0.3161
ROE:-125.23%
ROA:-64.90%
PB:6.87
PE(LYR):-4.33

Loading ...

Beyond Air Q1 Net Loss Slightly Widens, Reaffirms 2026 Outlook

Reuters
·
Aug 13

Sweden's RaySearch Q2 Order Intake Rises on Clinical Adoption

Reuters
·
Aug 13

RenovoRx Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook

Reuters
·
Aug 13

RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate

Benzinga Earnings
·
Aug 13

RenovoRx Q2 Net Loss Holds at $2.91 Million; Revenue More than Doubled to $909,000 Year over Year

Reuters
·
Aug 13

RenovoRx Q2 Net Income USD -2.911 Million

Reuters
·
Aug 13

RenovoRx - Raises Full-Year 2026 Revenue Guidance to $3.75 Mln-$4.25 Mln

THOMSON REUTERS
·
Aug 13

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

THOMSON REUTERS
·
Aug 13

RenovoRx - Trial Completion Expected H1 2027; Top Line Data Expected H2 2027

THOMSON REUTERS
·
Aug 11

RenovoRx Inc Expected to Post a Loss of 7 Cents a Share - Earnings Preview

Reuters
·
Aug 11

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

GlobeNewswire
·
Aug 06

RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar

TIPRANKS
·
Aug 05

RenovoRx Joins JonesTrading Webinar on TAMP Platform in Pancreatic Cancer

Reuters
·
Aug 04

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

GlobeNewswire
·
Jul 29

RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic?

Simply Wall St.
·
Jul 28

RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk

TIPRANKS
·
Jul 02

Renovorx Wins NASDAQ Extension to Regain $1 Minimum Bid Compliance

Reuters
·
Jul 02

RenovoRx Stockholders Approve Directors and Equity Plan

TIPRANKS
·
Jul 01

Renovorx Holds Annual Shareholder Meeting

Reuters
·
Jul 01